Addiction Therapeutics Market Size, Share and Growth Outlook, 2026

Addiction Therapeutics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Addiction Therapeutics Market size is forecast to increase from $10.99 Billion in 2026 to $18.6 Billion in 2034 at a CAGR of 6.8% between 2026 and 2034.

The Addiction Therapeutics market report provides detailed analysis and outlook of Addiction Therapeutics segments including By Drug Class (Opioid Addiction Therapies, Alcohol Addiction Therapies, Nicotine De-addiction Therapies, Non-Substance ), By Route of Administration (Oral, Parenteral, Transdermal Patches, Sublingual ), By Treatment Setting (Inpatient Treatment Centers, Outpatient Treatment Centers, Residential Rehabilitation Facilities), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Addiction Therapeutics Industry Overview

Advancing Precision Medicine Approaches in Addiction Treatment

The addiction therapeutics industry is increasingly focused on precision medicine, targeted pharmacology, and genetically guided treatment strategies to improve outcomes for individuals affected by substance use disorders. A notable development is the progress of AD04, a genetically targeted serotonin-3 receptor antagonist being developed by Adial Pharmaceuticals for Alcohol Use Disorder (AUD) in heavy-drinking patients with specific genetic profiles. The therapy is designed to address treatment variability through genotype-based patient selection, reflecting the growing emphasis on personalized addiction treatment. Regulatory momentum has further strengthened the program, as guidance from the U.S. FDA indicated that approval may be achievable through a single well-controlled Phase 3 trial supported by confirmatory evidence, reducing development complexity and anticipated clinical costs. Additionally, completion of demonstration batch manufacturing for AD04 has removed a key technical barrier, enabling progression toward late-stage registration studies.

Emergence of Novel Mechanisms for Alcohol Use Disorder

The market is also witnessing expansion into innovative therapeutic pathways aimed at addressing the biological drivers of addiction. Baseline Therapeutics launched as a clinical-stage biotechnology company dedicated exclusively to addiction therapeutics and introduced BT-001, a long-acting, once-weekly GLP-1 receptor agonist candidate. The therapy is being advanced to address compulsive behavior and craving mechanisms associated with Alcohol Use Disorder. Supported by an FDA-aligned clinical development strategy, the company plans multiple randomized, placebo-controlled Phase 3 studies while positioning the platform for future applications across broader substance use disorders. The growing interest in GLP-1 receptor agonists highlights the industry's shift toward therapies that target neurobehavioral and metabolic pathways involved in addiction.

Neurobiological and Stress-Response Targeted Innovation

Another significant trend involves targeting stress-related neurobiological mechanisms linked to addictive behaviors. Spruce Biosciences and HMNC Brain Health initiated patient dosing in the Phase 2 TAMARIND proof-of-concept study evaluating tildacerfont, an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist. The trial incorporates a proprietary genetic patient-selection platform to identify individuals whose major depressive disorder is associated with hypothalamic-pituitary-adrenal (HPA) axis dysregulation and heightened CRF neurotransmission. By modulating severe biological stress pathways, the therapy aims to influence interconnected psychiatric and addiction-related conditions, underscoring the industry's movement toward biomarker-driven and neuroscience-based addiction therapeutics.

Addiction Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Addiction Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Indivior PLC, Alkermes plc, Orexo AB (Zubsolv), Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Pfizer Inc., Eli Lilly and Company , Lundbeck A/S, Adial Pharmaceuticals , MediciNova, Inc.. The Addiction Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Addiction Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Addiction Therapeutics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Addiction Therapeutics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Addiction Therapeutics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Addiction Therapeutics Market Competitive Benchmarking and Company Analysis

Leading companies in Addiction Therapeutics industry include- Indivior PLC, Alkermes plc, Orexo AB (Zubsolv), Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Pfizer Inc., Eli Lilly and Company , Lundbeck A/S, Adial Pharmaceuticals , MediciNova, Inc.. The Addiction Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Addiction Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Addiction Therapeutics market remains one of the strongest-performing segments in the country.
The US Addiction Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Addiction Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Addiction Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Addiction Therapeutics markets

Canada's strong Addiction Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Addiction Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Addiction Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Addiction Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Addiction Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Addiction Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Addiction Therapeutics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Addiction Therapeutics sales through 2034

France Addiction Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Addiction Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Addiction Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Addiction Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Addiction Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Addiction Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Addiction Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Addiction Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Addiction Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Addiction Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Addiction Therapeutics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Addiction Therapeutics Market Segmentation

By Drug Class
Opioid Addiction Therapies
Alcohol Addiction Therapies
Nicotine De-addiction Therapies
Non-Substance
By Route of Administration
Oral
Parenteral
Transdermal Patches
Sublingual
By Treatment Setting
Inpatient Treatment Centers
Outpatient Treatment Centers
Residential Rehabilitation Facilities
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online

Top Companies in Addiction Therapeutics Industry

Indivior PLC
Alkermes plc
Orexo AB (Zubsolv)
Dr. Reddy’s Laboratories Ltd.
Hikma Pharmaceuticals PLC
Pfizer Inc.
Eli Lilly and Company
Lundbeck A/S
Adial Pharmaceuticals
MediciNova, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa